Liposomal Bupivacaine in Adductor Canal Blocks (ACB)

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether liposomal bupivacaine is superior to normal bupivacaine in terms of providing better pain control postoperatively after total knee arthroplasty.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Treatments: Bupivacaine; Ropivacaine

Criteria

Inclusion Criteria:

1. The subject is scheduled for elective unilateral primary TKA

2. The subject is ≥ 18 years

3. The subject's primary anesthesia care team has planned for a neuraxial anesthetic (i.e. spinal, epidural or combined-spinal epidural)

4. The patient consents for an adductor canal block

5. Willing and able to sign an informed consent.

Exclusion Criteria:

1. Patients unwilling or unable to consent to participate in the study.

2. Prisoners.

3. Pregnancy.

4. Reported to have mental illness or belonging to a vulnerable population.

5. Subject is < 18 years of age.

6. Patients receiving general anesthesia for the total knee arthroplasty.

7. Subject has impaired decision-making capacity per discretion of the Investigator.

8. Any condition for which the primary anesthesia care team deems neuraxial anesthesia inappropriate.

9. Significant pre-existing neuropathy on the operative limb.

10. Significant chronic pain disorders (i.e. fibromyalgia, complex regional pain syndrome I & II, among others).

11. Subject has sustained a significant trauma to the operative knee.

12. Chronic Opioid Use (daily or almost daily use of opioids for > 3 months).

13. Known hypersensitivity and/or allergies to local anesthetics.

14. Previous surgery on the affected knee excluding arthroscopic or open meniscectomy.

15. Patients with impaired renal function such that they cannot receive IV Toradol.